

## **Department of Planning and Budget**

### **2017 Fiscal Impact Statement**

**1. Bill Number:** SB 1403S1

<b>House of Origin</b>	<input type="checkbox"/> Introduced	<input checked="" type="checkbox"/> Substitute	<input type="checkbox"/> Engrossed
<b>Second House</b>	<input type="checkbox"/> In Committee	<input type="checkbox"/> Substitute	<input type="checkbox"/> Enrolled

**2. Patron:** Dunnivant

**3. Committee:** Education and Health

**4. Title:** Board of Pharmacy to deschedule or reschedule cannabidiol upon publication of an interim final rule.

**5. Summary:** Directs the Board of Pharmacy to initiate action to deschedule or reschedule cannabidiol or any product containing cannabidiol that has been approved as a prescription medication by the U.S. Food and Drug Administration pursuant to 21 U.S.C. § 360bb and 21 U.S.C. § 355 within 90 days of publication in the Federal Register of an interim final rule.

**7. No Fiscal Impact.**

**8. Fiscal Implications:** This bill would not have a fiscal impact on the Commonwealth. Any costs to the Board of Pharmacy to initiate action to reschedule cannabidiol are minimal and can be absorbed by the agency.

**9. Specific Agency or Political Subdivisions Affected:** None.

**10. Technical Amendment Necessary:** No.

**11. Other Comments:** HB 1799, introduced by Delegate O'Bannon, is a companion bill.